The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Sponsor: Celgene
Listed as NCT01566695, this PHASE3 trial focuses on Myelodysplastic Syndrome and remains completed. Sponsored by Celgene, it has been updated 35 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
35 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 30 earlier versions
-
Dec 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .